Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial
Prospective trial finds allogeneic stem cell transplantation improves event-free survival in myelofibrosis patients versus ruxolitinib, highlighting treatment risks.
Key Points
SCT significantly improves event-free survival compared to ruxolitinib in myelofibrosis patients, indicating better disease management.
Median event-free survival was not reached in the SCT group, while it was 18 months for the ruxolitinib group, demonstrating a clear advantage.
Prospective multicenter phase II trial comparing SCT and continued ruxolitinib in 87 patients shows significant efficacy differences in terms of survival rates.
These findings underscore the necessity for careful patient selection in myelofibrosis treatment to balance risks and benefits.